The partnership grants dsm-firmenich global access to ZERION A/S’s unique, cutting-edge Dispersome^® technology, developed with the aim of significantly increasing the bioavailability of oral cannabidiol (CBD) compared to commercially available CBD oils. Not only will the collaboration inspire a new generation of patient-first cannabinoid therapies, but it also enhances dsm-firmenich’s unrivalled end-to-end capabilities in the promising cannabinoid space.  

 The cornerstone of this partnership is dsm-firmenich's global access to ZERION A/S’s groundbreaking Dispersome® technology, heralded for its capacity to significantly enhance the bioavailability of oral cannabidiol (CBD), surpassing conventional CBD oils. This proprietary technology promises to catapult cannabinoid formulations to new heights, ensuring optimized therapeutic outcomes for patients worldwide.

The inherent challenge of limited oral bioavailability in cannabinoid molecules, particularly CBD, has long impeded their widespread efficacy. However, the collaborative efforts between dsm-firmenich and ZERION A/S are poised to surmount this obstacle by leveraging the cutting-edge Dispersome® technology. Through this innovative approach, CBD formulations boasting three to four times higher drug loading than existing products are now within reach, promising unparalleled efficacy and patient satisfaction.

Dr. Zdravka Misic, Innovation Manager at dsm-firmenich, emphasized the patient-centric ethos driving this transformative initiative. "Our journey in the realm of cannabinoids has always been anchored in prioritizing patient welfare. By harnessing our formulation expertise in tandem with ZERION A/S’s pioneering technology, we've achieved a paradigm shift in cannabinoid therapy. Our novel formulations strike an optimal balance between API loading, stability, and pharmacokinetic profile, heralding a new dawn of patient-centric solutions."

Kelsey Achenbach, Senior Director of Pharma and Medical Nutrition at dsm-firmenich, underscored the company's unwavering commitment to innovation and collaboration. "We're steadfast in our resolve to surmount barriers in cannabinoid research, and our partnership with ZERION A/S stands testament to this commitment. Bolstered by synergistic collaborations with industry leaders like Brains Bioceutical, we're poised to redefine cannabinoid therapy, empowering patients and clinicians alike."

Looking ahead, dsm-firmenich has unveiled plans for a comprehensive pharmacokinetic study slated for 2024. This study aims to evaluate the bioavailability of their groundbreaking THC-free, GMP-certified, pharma-grade CBD formulations developed utilizing the Dispersome® technology. These formulations hold immense promise across diverse therapeutic domains, including CNS diseases, pain management, mood disorders, and oncology, underscoring their multifaceted potential to revolutionize patient care on a global scale.